| 761334 |
BLA | ZYNYZ | RETIFANLIMAB-DLWR | INJECTABLE;INTRAVENOUS | 2023-03-22 | INCYTE CORP |
| 761324 |
BLA | EPKINLY | EPCORITAMAB-BYSP | INJECTABLE;SUBCUTANEOUS | | GENMAB US, INC. |
| 761310 |
BLA | ELAHERE | MIRVETUXIMAB SORAVTANSINE-GYNX | INJECTABLE;INJECTION | 2022-11-14 | IMMUNOGEN INC |
| 761291 |
BLA | TECVAYLI | TECLISTAMAB-CQYV | INJECTABLE;INJECTION | 2022-10-25 | JANSSEN BIOTECH |
| 761289 |
BLA | IMJUDO | TREMELIMUMAB-ACTL | INJECTABLE;INTRAVENOUS | 2022-10-21 | ASTRAZENECA AB |
| 761278 |
BLA | LAMZEDE | VELMANASE ALFA-TYCV | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 2023-02-16 | CHIESI FARMACEUTICI SPA |
| 761270 |
BLA | IMJUDO | TREMELIMUMAB-ACTL | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 2022-11-10 | ASTRAZENECA AB |
| 761269 |
BLA | LEQEMBI | LECANEMAB-IRMB | INJECTABLE;INJECTION | 2023-01-06 | EISAI INC |
| 761268 |
BLA | VEGZELMA | BEVACIZUMAB-ADCD | INJECTABLE;INJECTION | 2022-09-27 | CELLTRION |
| 761263 |
BLA | LUNSUMIO | MOSUNETUZUMAB-AXGB | INJECTABLE;INJECTION | 2022-12-22 | GENENTECH INC |
| 761262 |
BLA | SKYRIZI | RISANKIZUMAB-RZAA | INJECTABLE;INTRAVENOUS | 2022-06-16 | ABBVIE INC |
| 761261 |
BLA | XENPOZYME | OLIPUDASE ALFA-RPCP | INJECTABLE;INJECTION | 2022-08-31 | GENZYME CORP |
| 761255 |
BLA | IDACIO | ADALIMUMAB-AACF | INJECTABLE;SUBCUTANEOUS | 2022-12-13 | FRESENIUS KABI USA |
| 761244 |
BLA | SPEVIGO | SPESOLIMAB-SBZO | INJECTABLE;INTRAVENOUS | 2022-09-01 | BOEHRINGER INGELHEIM PHARMACEUTICALS INC |
| 761238 |
BLA | BRIUMVI | UBLITUXIMAB-XIIY | INJECTABLE;INTRAVENOUS | 2022-12-28 | TG THERAPEUTICS, INC |
| 761235 |
BLA | VABYSMO | FARICIMAB-SVOA | INJECTABLE; INTRAVITREAL | 2022-01-28 | GENENTECH INC |
| 761234 |
BLA | OPDUALAG | NIVOLUMAB;RELATLIMAB-RMBW | SOLUTION;INTRAVENOUS | 2022-03-18 | BRISTOL MYERS SQUIBB |
| 761231 |
BLA | ALYMSYS | BEVACIZUMAB-MALY | INJECTABLE;INJECTION | 2022-04-13 | AMNEAL PHARMS LLC |
| 761228 |
BLA | KIMMTRAK | TEBENTAFUSP-TEBN | INJECTABLE;INJECTION | 2022-01-25 | IMMUNOCORE LTD |
| 761224 |
BLA | TEZSPIRE | TEZEPELUMAB-EKKO | SOLUTION;SUBCUTANEOUS | 2021-12-17 | ASTRAZENECA AB |
